Sanofi eyes German insulin investment of up to $1.6 bln, source says
Adds context on French politics in fourth paragraph, details on Novo Nordisk in paragraphs 8 and 9
BERLIN, July 1 (Reuters) -French drugmaker Sanofi SASY.PA is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person familiar with the plan told Reuters on Monday.
The expected investment would be the latest in a string of recent wins by Germany's ruling coalition to attract foreign investments, particularly in the pharmaceuticals sector.
German newspaper Handelsblatt, which first reported the investment plan on Monday, cited German government sources as saying Sanofi had changed course after initially considering shifting production of its insulin brand Lantus to France, and was now close to committing to an upgrade of its German site in Frankfurt's Hoechst district.
Sanofi's possible expansion in Germany comes as France's far-right National Rally scored major wins in the first round of parliamentary elections, fuelling uncertainty over what a potential shift in political power could mean for business, though the source did not mention political factors as possible influences and gave no reason for favouring Germany.
The company said it would not comment on specific investment projects. A German government spokesperson said Chancellor Olaf Scholz was "very much looking forward" to further developments but it was for the company to provide an update.
Among recent wins by Germany's ruling coalition in attracting healthcare investments, Daiichi Sankyo 4568.T said in February it would spend about 1 billion euros to boost its work on precision cancer drugs near Munich.
U.S. drugmaker Eli Lilly LLY.N in November last year pledged to invest 2.3 billion euros to make obesity and diabetes drugs in Germany.
The world's other largest insulin maker, Novo Nordisk NOVOb.CO, meanwhile, has recently showed signs of prioritising manufacturing of its blockbuster obesity drug Wegovy, and diabetes drug Ozempic, which contains the same active ingredient, over the production of insulin.
In November for example Novo announced it would discontinue one of its insulins, Levemir, citing manufacturing constraints among other issues.
Scholz's coalition government, whose three constituent parties suffered big losses in European elections last month, is eager to bolster its economic credentials ahead of general elections next year.
Europe's biggest economy is expected to return to growth of 0.3% to 0.4% this year, after a 0.3% contraction in 2023, which was the weakest performance among big euro zone countries.
But foreign companies announced record levels of new investment in Germany last year despite the downturn and high energy prices, a report showed in May.
Reporting by Klaus Lauer in Berlin; Additional reporting by Maggie Fick; Writing by Ludwig Burger and Christoph Steitz; Editing by Susan Fenton and David Holmes
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.